1. Hauptnavigation
  2. Navigation des Hauptbereiches
  3. Inhalt der Seite

Press Officer and Head of Press and Public Relations

Dr. Stefanie Seltmann
Dr. Stefanie Seltmann

Im Neuenheimer Feld 280
69120 Heidelberg

Phone: +49 6221 422854
Fax: +49 6221 422968

E-Mail: s.seltmann@dkfz.de
or presse@dkfz.de

Recent Press Releases

No. 14 | 18. March 2015 | by Koh

Selective inhibition of a specific enzyme reduces side effects

Selective inhibition of a specific enzyme reduces side effects

In cases of neuroblastoma, which is an aggressive type of cancer in children, tumor growth can be slowed down by selective inhibition of a specific cancer-promoting enzyme. Scientists from the German Cancer Research Center (DKFZ) have now shown in experiments that this leads to less aggressive growth of the cancer cells. Treatment outcomes can be enhanced even further by combining the inhibitor with a vitamin A derivative that also supports the differentiation of the immature cells into neurons.

No. 13a | 11. March 2015 | by nis

German-Israeli exchange in science management

German-Israeli exchange in science management

For over 25 years, the German Cancer Research Center (DKFZ) and Heidelberg University have been maintaining a consistent and intensive exchange with Israeli scientific research institutes. Every two years, administrative representatives from various Israeli universities and the Weizmann Institute meet with representatives of Heidelberg University and the DKFZ at a conference held alternately between Israel and Heidelberg. This year, the DKFZ and Heidelberg University will be hosting the 15th Israeli-German Administrators’ Conference (IGAC) on March 16-19. Over 60 participants will be in attendance.

No. 13 | 11. March 2015 | by Koh

Deadly to cancer cells only: A molecular cause for selective effectiveness of parvovirus therapy discovered

Deadly to cancer cells only: A molecular cause for selective effectiveness of parvovirus therapy discovered

Parvoviruses can destroy cancer cells and are currently being tested in a preliminary clinical trial to treat malignant brain cancer. For their replication, the viruses need a particular enzyme in the cell. Scientists from the German Cancer Research Center (DKFZ) have now discovered that in healthy human cells, parvoviruses are unable to activate this enzyme. In many cases of malignant brain cancer, however, the enzyme is permanently active. As a result, this enables the viruses to replicate and to destroy the cancer cells. It accounts not only for the viruses' natural selectivity for cancer cells but also helps identify cancer patients who might benefit from parvovirus therapy.

Audio (in German only)
einblick (in German only)
Publications
Videos (in German only)
last update: 16/10/2013 back to top